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Molecular Cardiology
Conditional Transgenic Expression of Fibroblast Growth
Factor 9 in the Adult Mouse Heart Reduces Heart Failure
Mortality After Myocardial Infarction
Mortimer Korf-Klingebiel, PhD; Tibor Kempf, MD; Klaus-Dieter Schlu¨ter, MD;
Christian Willenbockel, DVM; Torben Brod, BS; Jo¨rg Heineke, MD; Volker J. Schmidt, MD;
Franziska Jantzen, PhD; Ralf P. Brandes, MD; Peter H. Sugden, PhD; Helmut Drexler, MD;†
Jeffery D. Molkentin, PhD; Kai C. Wollert, MD
Background—Fibroblast growth factor 9 (FGF9) is secreted from bone marrow cells, which have been shown to improve
systolic function after myocardial infarction (MI) in a clinical trial. FGF9 promotes cardiac vascularization during
embryonic development but is only weakly expressed in the adult heart.
Methods and Results—We used a tetracycline-responsive binary transgene system based on the -myosin heavy chain
promoter to test whether conditional expression of FGF9 in the adult myocardium supports adaptation after MI. In
sham-operated mice, transgenic FGF9 stimulated left ventricular hypertrophy with microvessel expansion and preserved
systolic and diastolic function. After coronary artery ligation, transgenic FGF9 enhanced hypertrophy of the
noninfarcted left ventricular myocardium with increased microvessel density, reduced interstitial fibrosis, attenuated
fetal gene expression, and improved systolic function. Heart failure mortality after MI was markedly reduced by
transgenic FGF9, whereas rupture rates were not affected. Adenoviral FGF9 gene transfer after MI similarly promoted
left ventricular hypertrophy with improved systolic function and reduced heart failure mortality. Mechanistically, FGF9
stimulated proliferation and network formation of endothelial cells but induced no direct hypertrophic effects in neonatal
or adult rat cardiomyocytes in vitro. FGF9-stimulated endothelial cell supernatants, however, induced cardiomyocyte
hypertrophy via paracrine release of bone morphogenetic protein 6. In accord with this observation, expression of bone
morphogenetic protein 6 and phosphorylation of its downstream targets SMAD1/5 were increased in the myocardium
of FGF9 transgenic mice.
Conclusions—Conditional expression of FGF9 promotes myocardial vascularization and hypertrophy with enhanced
systolic function and reduced heart failure mortality after MI. These observations suggest a previously unrecognized
therapeutic potential for FGF9 after MI. (Circulation. 2011;123:504-514.)
Key Words: angiogenesis  cardiac remodeling  FGF9  mortality  myocardial infarction
Advances in treatment have resulted in declining mortal-ity rates after acute myocardial infarction (MI). Unfor-
tunately, the decrease in postinfarct mortality is paralleled by
an increase in the incidence of heart failure in patients
surviving with significant residual myocardial damage.1 Loss
of contractile tissue after MI induces profound alterations of
left ventricular (LV) tissue architecture that are characterized
by chamber dilatation and pathological hypertrophy of the
noninfarcted myocardium, leading to contractile dysfunction
and reduced long-term survival.2
Clinical Perspective on p 514
During midgestational heart development, the heart under-
goes a dramatic increase in size that is attributable to
cardiomyoblast proliferation and the concurrent formation of
the coronary vascular system.3,4 LV contractile function
increases during this period of rapid cardiac growth,5 thus
providing an example that cardiac mass and size can increase
considerably without deleterious effects on systolic function
or lifespan. Fibroblast growth factor (FGF) 9 acts as an
Received April 1, 2010; accepted November 23, 2010.
From the Hans-Borst-Center for Heart and Stem Cell Research, Department of Cardiology and Angiology, Hannover Medical School, Hannover,
Germany (M.K.K., T.K., C.W., T.B., J.H., V.J.S., F.J., H.D., K.C.W.); Institute of Physiology, Justus-Liebig-University, Gießen, Germany (K.D.S.);
Institute of Cardiovascular Physiology, Johann-Wolfgang-Goethe-University, Frankfurt am Main, Germany (R.P.B.); Institute for Cardiovascular and
Metabolic Research, University of Reading, Reading, UK (P.H.S.); and Division of Molecular Cardiovascular Biology and Howard Hughes Medical
Institute, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Ohio (J.H., J.D.M.).
†Deceased.
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.110. 989665/DC1.
Correspondence to Kai C. Wollert, Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover,
Germany. E-mail wollert.kai@mh-hannover.de
© 2011 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.110.989665
504
 at UNIV OF READING - LIBRN on February 11, 2013http://circ.ahajournals.org/Downloaded from 
essential inducer of midgestational cardiac growth and
vascularization.6,7
FGF9 is a member of the FGF gene family, which
comprises 22 functionally diverse polypeptides in humans
and mice that can be divided into subfamilies based on their
chromosomal location and evolutionary relationships, their
function as intracellular or secreted proteins, and their bio-
chemical properties.8 FGF9 acts as a secreted factor and
exerts its functions via transmembrane FGF receptors on
target cells.8,9 Because of its affinity for pericellular heparan
sulfate proteoglycans, FGF9 diffuses locally within tissues
and acts primarily in a paracrine fashion.10 During midges-
tation, FGF9 is expressed by the epicardium and endocardium
and provides an epithelial-to-mesenchymal signal to stimu-
late coronary artery formation and cardiomyoblast expansion
in the developing myocardium.6,7 FGF9 is expressed only at
low levels in the adult heart,11 and previous transcriptome
analyses provided no evidence for a reinduction of FGF9
expression after MI.12
We have recently shown that FGF9 is secreted from bone
marrow cells (BMCs) that we have found in a randomized
controlled cell therapy trial to enhance the recovery of LV
ejection fraction in patients after MI.13,14 Paracrine mecha-
nisms are thought to contribute to the beneficial effects of
BMCs on perfusion and function of the infarcted heart that
have been demonstrated in experimental studies and some
clinical trials.15,16 Considering the pivotal role of FGF9 in
supporting cardiac growth and vascularization during devel-
opment, we therefore hypothesized that increased expression
levels of FGF9 may help the heart adapt to a MI. Our data
indicate that conditional transgenic expression of FGF9 in the
adult mouse myocardium promotes adaptive LV hypertrophy
with enhanced systolic function and reduced heart failure
mortality after MI, thus pointing to FGF9 as a potential
therapeutic strategy after MI.
Methods
An expanded Methods section is provided in the online-only
Data Supplement.
Mouse and rat cells were stimulated with recombinant mouse
FGF9 and bone morphogenetic protein 6 (BMP6), human cells with
recombinant human FGF9. Dorsomorphin was used as an inhibitor
of activin receptor-like kinase (ALK) 2, ALK3, and ALK6.17
SB-431542 was used as an inhibitor of ALK4, ALK5, and ALK7.18
A tetracycline-responsive transgene system19 was used to allow
temporally regulated expression of FGF9 in adult cardiac myocytes.
Mouse FGF9 cDNA was placed under the chimeric tetracycline-
responsive -myosin heavy chain (MHC) promoter (responder
mice). FGF9 transgenic mice were crossed with transgenic mice
expressing the tetracycline transactivator (tTA) under the control of
the constitutive MHC promoter. All mice were generated and bred
on an FVB/N background. Doxycycline was provided in the drinking
water from mating up to 8 weeks after birth to inhibit FGF9
transgene expression; doxycycline was then withdrawn to induce
FGF9 expression.
MI was induced in male mice by permanent left anterior descend-
ing coronary artery (LAD) ligation during isoflurane anesthesia. A
sham operation was performed in control mice. Mice were followed
up and inspected daily from 24 hours up to 6 weeks after MI.
Autopsies were performed on all dead animals; rupture was diag-
nosed by the presence of a blood clot around the heart and in the
chest cavity; heart failure was diagnosed by chest fluid
accumulation.20,21
Replication-deficient adenoviruses encoding mouse FGF9 (Ad.FGF9) or
-galactosidase (Ad.lacZ) were injected into the LV cavity immediately
after LAD ligation.
Steady-state LV pressure-volume loops were recorded with a 1.4F
micromanometer conductance catheter (SPR-839, Millar Instru-
ments, Houston, TX) inserted via the right carotid artery during
isoflurane anesthesia. Transthoracic echocardiography was per-
formed with a linear 30-MHz transducer in mice sedated with
isoflurane.
Infarct sizes were determined in paraffin-embedded tissue sections
stained with Masson trichrome. Infarct sizes were calculated as the
average ratio of endocardial scar length to endocardial total LV
circumference in basal, midventricular, and apical sections. Scar
thickness was measured at the center of the infarct in the same
sections. Midventricular cryosections were prepared for fluorescent
(immuno)staining. Cardiomyocytes were outlined by TRITC-
conjugated wheat germ agglutinin (WGA). The circumferences of 40
to 50 myocytes were traced and digitized to calculate mean cardio-
myocyte cross-sectional area. Ki67 was detected with a rabbit
polyclonal antibody; troponin T, with a mouse monoclonal antibody.
Capillaries were stained with fluorescein-labeled GSL I-isolectin B4.
Conductance vessels were identified by their diameter (20 m)
after immunostaining for smooth muscle -smooth muscle actin
(SMA). Interstitial collagen content was determined by Picrosirius
Red polarization microscopy.
Cardiac gene expression levels were quantified by quantitative
polymerase chain reaction (polymerase chain reaction primers are
shown in Table I in the online-only Data Supplement).
Human coronary artery endothelial cells (HCAECs) were pur-
chased from Provitro (Berlin, Germany). Primary mouse heart
endothelial cells were isolated as previously described.22 Endothelial
cell proliferation was measured by bromodeoxyuridine incorpora-
tion. Network formation was assayed in tissue culture plates coated
with growth factor–reduced Matrigel. Ventricular cardiomyocytes
were isolated from 1- to 3-day-old Sprague-Dawley rats by Percoll
density gradient centrifugation. Cell size was determined by planim-
etry; protein content was assessed by the Bradford assay. Adult
ventricular cardiomyocytes were isolated from 4-month-old Wistar
rats. Cross-sectional area of adult cardiomyocytes was calculated as
follows: (cell width/2)2. Net protein synthesis was measured by
[14C] phenylalanine incorporation.
Antibodies against mouse FGF9, BMP6, phospho-SMAD1/5,
phospho-SMAD3, and -actin were used for immunoblotting. Ex-
pression levels of 174 secreted factors were assessed in conditioned
HCAEC supernatants with Human Cytokine ProteinChip Array C
Series 2000 membranes (Ray Biotech, Norcross, GA).
Statistical Analysis
Data are presented as meanSEM. The unpaired t test was used for
comparisons between 2 groups. For comparisons between 2
groups, we used 1-way ANOVA if there was 1 independent variable
and 2-way ANOVA if there were 2 independent variables (ie,
genotype and LAD ligation status). The Tukey posthoc test was used
to adjust for multiple comparisons. Pairwise comparisons were made
between sham groups across genotypes, sham versus MI within each
genotype, and MI groups across genotypes. Kaplan–Meier curves
were created to illustrate cumulative mortality after MI, and statis-
tical assessment was performed by the log-rank test. A 2-tailed value
of P0.05 was considered to indicate statistical significance.
Results
Generation of Inducible, Cardiac-Specific FGF9
Transgenic Mice
Inducible and heart-specific expression of FGF9 was
achieved with a binary MHC promoter-based transgene
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strategy (Figure 1A). Two independent responder transgenic
lines were generated (lines 1 and 3). Each permitted expres-
sion of FGF9 in the heart only in the presence of the driver
transgene encoding the tTA when doxycycline was absent. In
all experiments, doxycycline was administered from mating
up to 8 weeks after birth, which blocks developmental
expression, followed by doxycycline withdrawal thereafter to
permit transgene expression starting in young adulthood
(Figure 1B). In tTA/FGF9 double transgenic (DTG) mice
from line 1, LV FGF9 protein expression was increased
6.3-fold at 2 weeks and 4.8-fold at 8 weeks after doxycycline
withdrawal compared with wild-type (WT) mice (Figure 1C
and 1D). A similar degree of FGF9 induction was observed in
line 3 (Figure 1C and 1D). Data from line 1 are presented
here. Line 3 displayed an identical cardiac phenotype (not
shown).
FGF9 Promotes Cardiac Hypertrophy
To assess the effects of prolonged FGF9 expression on the
adult unstressed myocardium, mice were followed up for up
to 8 weeks after doxycycline withdrawal. Mice underwent a
sham operation 2 weeks after doxycycline removal to allow
comparison with mice undergoing LAD ligation at this time
point (see below). No increase in LV mass was apparent at 2
weeks, but after 8 weeks of doxycycline withdrawal, LV
mass (Figure 2A) and the ratio of LV mass to body mass
(Figure 2B) were increased in DTG compared with WT and
tTA control mice. No differences in body weight were
observed between the genotypes (not shown). The increases
in LV mass and heart size (Figure 2C) in DTG mice were
related to an increase in LV wall thickness with no apparent
increase in LV cavity diameter (Figure 2D). On histological
examination, DTG mice displayed a significant increase in
Figure 1. Inducible, cardiac-specific FGF9 trans-
genic mice. A, Schematic representation of the
binary transgene system. B, Time schedule of
doxycycline (Dox) treatment and FGF9 transgene
expression (blue, FGF9 not expressed; white,
FGF9 expressed). C, Immunoblots showing FGF9
expression in the LV myocardium at 8 weeks of
age (mice still on Dox) and at 10 and 16 weeks of
age (mice off Dox for 2 or 8 weeks) in WT, tTA sin-
gle transgenic, and tTA/FGF9 DTG mice from lines
1 and 3. D, Quantification of FGF9 protein expres-
sion (8 to 10 animals per group).
Figure 2. FGF9 promotes cardiac hyper-
trophy. LV mass (A) and ratio of LV mass
to body mass (B) in WT, tTA single
transgenic, and tTA/FGF9 DTG mice 2
and 8 weeks after doxycycline (Dox)
withdrawal. Hearts (C) and transverse
heart sections (D) stained with Masson
trichrome 8 weeks after Dox withdrawal.
E, LV tissue sections stained with WGA
and DAPI or Masson trichrome 8 weeks
after Dox removal (scale bar, 100 m). F,
Mean LV cardiomyocyte cross-sectional
area (CSA) 2 and 8 weeks after Dox
withdrawal; 8 animals per group in A, B,
and F.
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LV cardiomyocyte cross-sectional area 8 weeks after
doxycycline withdrawal compared with WT and tTA
controls (Figure 2E and 2F). Expression of transcripts of
atrial natriuretic peptide, MHC, MHC, sarco(endo)plas-
mic reticulum Ca2 ATPase 2a (SERCA2a), and phospho-
lamban was not significantly different between WT, tTA,
and DTG mice (Table II in the online-only Data Supple-
ment, sham).
No differences in tail-cuff blood pressure or heart rate were
observed between the 3 genotypes after 8 weeks of doxycy-
cline treatment or during 8 weeks after doxycycline with-
drawal (Figure I in the online-only Data Supplement, sham).
Eight weeks after doxycycline withdrawal, invasive
pressure-volume measurements revealed no significant
differences between the 3 genotypes with regard to LV
end-diastolic or end-systolic volumes and several indexes
of systolic and diastolic function (Table 1, sham). Typical
pressure-volume loops are shown in Figure II in the
online-only Data Supplement. On 2-dimensional echocar-
diography, DTG mice displayed an increase in LV poste-
rior wall thickness, normal internal LV dimensions, and
preserved systolic function (Table III in the online-only
Data Supplement, sham).
FGF9 Enhances Microvessel Density in
the Myocardium
Two weeks after doxycycline withdrawal, the density of
proliferating, Ki67 isolectin B4 endothelial cells was
increased in the LV myocardium of DTG mice (Figure 3A
and 3B). Eight weeks after doxycycline withdrawal, Ki67
endothelial cell density remained elevated in DTG mice and
was accompanied by an increase in capillary density (Figure
3A and 3C) and an increase in the density of small (20 to
50 m in diameter) SMA conductance vessels (Figure 3A
and 3D). Two and 8 weeks after doxycycline withdrawal, no
Ki67 cardiomyocyte nuclei were detectable in multiple
tissue sections stained with anti-Ki67 and anti–troponin T
antibodies and DAPI (not shown).
Eight weeks after doxycycline withdrawal, no significant
differences emerged between the genotypes (4 to 6 mice per
group) in the density of larger (50 m) SMA vessels
(WT, 0.380.13; tTA, 0.400.06; DTG, 0.330.05 vessels
per 100 cardiomyocytes) and interstitial collagen volume
fraction in the LV myocardium (WT, 0.170.01%; tTA,
0.160.01%; DTG, 0.170.01%).
FGF9 Stimulates Endothelial Cell Proliferation,
Network Formation, and Release of
Prohypertrophic Factor(s)
Cardiomyocyte hypertrophy and microvessel expansion rep-
resented the main phenotypes observed in FGF9-expressing
DTG mice. To explore whether FGF9 has a direct effect on
cardiomyocyte hypertrophy, we stimulated neonatal cardio-
myocytes with increasing concentrations of FGF9. Only at
high concentrations (100 ng/mL) did FGF9 promote an
increase in cardiomyocyte size, which was, however, much
less pronounced than the response to endothelin 1 that we
used as a positive control (Figure 4A). FGF9 did not promote
a significant increase in cardiomyocyte protein content,
which was chosen as an additional readout of hypertrophy
(Figure III in the online-only Data Supplement).
Although cardiomyocytes were only weakly responsive
to FGF9, HCAECs responded to markedly lower concen-
trations (10 ng/mL) of FGF9 with proliferation (Figure
4B) and network formation (Figure 4C and 4D). The
effects of FGF9 on HCAECs were at least as potent as the
effects of vascular endothelial growth factor, which we
used as positive control.
Table 1. Invasive Pressure-Volume Measurements 6 Weeks
After Sham Operation or LAD Ligation
WT tTA DTG
Sham, n 5 6 6
Heart rate, bpm 54116 53024 49916
LV end-systolic
volume, L
111 133 132
LV end-diastolic
volume, L
323 323 353
LV end-systolic
pressure, mm Hg
795 857 843
LV end-diastolic
pressure, mm Hg
71 92 91
Ejection fraction, % 714 686 682
Cardiac output,
L/min
125951677 11760544 12371689
Stroke work,
mm HgL
1861310 1884177 2055143
dP/dtmax, mm Hg/s 11464904 10615745 104481120
dP/dtmin, mm Hg/s 7126392 7985472 8331353
 w, ms 6.50.4 6.40.4 6.40.4
LAD ligation, n 10 11 13
Heart rate, bpm 48917 5126 49613
LV end-systolic
volume, L
394‡ 403‡ 273†§¶
LV end-diastolic
volume, L
493* 503† 413
LV end-systolic
pressure, mm Hg
813 753 844
LV end-diastolic
pressure, mm Hg
102 71 81
Ejection fraction, % 273‡ 262‡ 433‡#
Cardiac output,
L/min
6316385‡ 6501387† 8915738*§¶
Stroke work,
mm HgL
844147† 69048‡ 1260123†§#
dP/dtmax, mm Hg/s 6027494† 6024318‡ 7828376#
dP/dtmin, mm Hg/s 4750399† 4857274† 5756239‡
 w, ms 10.31.0† 8.70.5† 8.50.6*
WT, tTA single transgenic, and tTA/FGF9 DTG mice were treated with
doxycycline from mating until 8 weeks after birth. Doxycycline was then
withdrawn. Mice underwent a sham operation or LAD ligation 2 weeks after
doxycycline withdrawal. Hemodynamic measurements were performed 6
weeks later.
*P0.05, †P0.01, ‡P0.001 versus same genotype sham; §P0.05,
P0.01 versus WT LAD ligation; ¶P0.05, #P0.01 versus tTA LAD ligation.
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These data led us to hypothesize that FGF9 induces
cardiomyocyte hypertrophy by stimulating endothelial cells
to release prohypertrophic factor(s). Indeed, conditioned su-
pernatants from HCAECs stimulated for 24 hours with 10
ng/mL FGF9 promoted a significant increase in cardiomyo-
cyte size, whereas conditioned supernatants from unstimu-
lated HCAECs did not (Figure 4E and 4F). Similar results
were obtained when protein content was used as a readout of
hypertrophy (Figure 4G).
BMP6 Is Induced by FGF9 In Vitro and In Vivo
and Stimulates Cardiomyocyte Hypertrophy
An antibody array detecting 174 cytokines, chemokines, and
growth factors was used to identify factors secreted from HCAECs
stimulated with 10 ng/mL FGF9 for 24 hours. Nine secreted
factors were induced 2-fold by FGF9 in 2 independent array
analyses (Table IV in the online-only Data Supplement). BMP6
was induced 2.5-fold and 6.8-fold in the 2 experiments, and its
average increase was greater than for any other factor.
Figure 3. FGF9 enhances microvessel
density in the myocardium. A, LV tissue
sections from WT, tTA single transgenic,
and tTA/FGF9 DTG mice stained with
anti-Ki67 antibody and isolectin B4 to
detect proliferating endothelial cells (top
row), with isolectin B4 to detect capillar-
ies (cardiomyocyte borders highlighted
by WGA staining; middle row), and with
anti-SMA antibody to detect conduc-
tance vessels (cardiomyocyte borders
highlighted by WGA staining; bottom
row) 8 weeks after doxycycline (Dox)
withdrawal (scale bars, 50 m). Quantifi-
cation of Ki67 isolectin B4 cell density
(B), capillary density (C), and conduc-
tance vessel (D; 20 to 50 m) density in
LV myocardium 2 and 8 weeks after Dox
withdrawal (4 to 6 animals per group).
Figure 4. FGF9 stimulates endothelial
cell proliferation, network formation, and
release of prohypertrophic factor(s). A,
Cell size of neonatal cardiomyocytes
stimulated for 24 hours with 100 nmol/L
endothelin 1 (ET1) or increasing concen-
trations of FGF9 (3 experiments;
*P0.05, ***P0.001 vs control). Prolifer-
ation (B) and network formation (C) of
HCAECs stimulated for 24 hours with 10
ng/mL vascular endothelial growth factor
(VEGF) or increasing concentrations of
FGF9 (3 to 5 experiments; *P0.05,
**P0.01 vs control). D, Images of
HCAECs under control conditions and
after stimulation with 10 ng/mL FGF9. E,
Images of neonatal cardiomyocytes kept
for 24 hours under control conditions or
stimulated with 100 nmol/L ET1, 10
ng/mL FGF9, supernatant (1:2 dilution)
obtained from HCAECs kept for 24
hours in serum-free medium (control
HCAEC-SN), or supernatant (1:2 dilution)
obtained from HCAECs stimulated for 24
hours with 10 ng/mL FGF9 (FGF9
HCAEC-SN); cells were stained with an
anti–troponin T antibody and DAPI. Cell
size (F) and protein content (G) of neo-
natal cardiomyocytes kept for 24 hours
under the conditions described in E (4 to
6 experiments).
508 Circulation February 8, 2011
 at UNIV OF READING - LIBRN on February 11, 2013http://circ.ahajournals.org/Downloaded from 
The effects of FGF9-stimulated HCAEC supernatants on
neonatal cardiomyocyte size were reduced by 79% by a
neutralizing anti-BMP6 antibody, indicating that BMP6 is
responsible for a substantial part of the paracrine prohyper-
trophic effect (Figure 5A). Corroborating this finding, we
found that recombinant BMP6 promoted a robust increase in
cardiomyocyte size in concentrations as low as 1 ng/mL
(Figure 5A). The effects of BMP6 on cardiomyocyte size
were abolished by the ALK2/3/6 inhibitor dorsomorphin but
not by the ALK4/5/7 inhibitor SB-431542 (Figure 5A).
Similarly, BMP6 promoted an increase in cardiomyocyte
protein content in an ALK2/3/6-dependent manner (Figure IV
in the online-only Data Supplement). Consistent with signal-
ing events downstream of ALK2/3/6,23 BMP6 enhanced
phosphorylation of SMAD1/5, but not SMAD3, in neonatal
cardiomyocytes (Figure 5B).
Consistent with our observations in HCAECs, FGF9 stim-
ulated proliferation and network formation of mouse heart
endothelial cells (Figure VA and VB in the online-only Data
Supplement), and FGF9-stimulated mouse endothelial cell
supernatants promoted increases in neonatal cardiomyocyte
size and protein content via paracrine release of BMP6
(Figure VC and VD in the online-only Data Supplement).
Like neonatal cardiomyocytes, adult cardiomyocytes re-
sponded to BMP6, but not FGF9, with a significant hyper-
trophic response characterized by increases in cross-sectional
area (Figure 5C and 5D) and [14C] phenylalanine incorpora-
tion (Figure 5E).
Eight weeks after doxycycline withdrawal, expression
levels of BMP6 and phosphorylated SMAD1/5, but not
phosphorylated SMAD3, were increased in the LVs of
FGF9-expressing DTG mice, showing that FGF9 enhances
the expression of BMP6 and activation of BMP6 downstream
targets in vivo (Figure 5F).
LV Hypertrophy With Microvessel Expansion and
Reduced Fibrosis After MI in
FGF9-Expressing Mice
To explore the effects of transgenic FGF9 in the setting of
MI, WT, tTA, and DTG mice underwent LAD ligation 2
weeks after doxycycline withdrawal and were followed up for
an additional 6 weeks. Expression levels of endogenous
FGF9 in the noninfarcted LV myocardium of WT mice did
not change during this time period (Figure 6A). The ratio of
scar length to endocardial circumference and scar thickness
Figure 5. BMP6 is induced by FGF9 in vitro and in vivo and stimulates cardiomyocyte hypertrophy. A, Cell size of neonatal cardiomyo-
cytes stimulated for 24 hours with supernatant (1:2 dilution) obtained from HCAECs kept for 24 hours in serum-free medium or stimu-
lated for 24 hours with 10 ng/mL FGF9 (control and FGF9 HCAEC-SN). When indicated, a BMP6-neutralizing antibody or control anti-
body (20 g/mL each) was added to the FGF9 HCAEC-SN. Cardiomyocytes were also stimulated with increasing concentrations of
BMP6 in the presence or absence of the ALK2/3/6 inhibitor dorsomorphin (DM; 20 mol/L) or the ALK4/5/7 inhibitor SB-431542 (SB;
20 mol/L) (3 experiments). B, Immunoblot analysis of phospho-SMAD1/5 and phospho-SMAD3 expression in neonatal cardiomyo-
cytes in response to stimulation with 10 ng/mL BMP6 for the indicated times (data are representative of 3 experiments). Cross-
sectional area (CSA; C) and [14C] phenylalanine incorporation (E) of adult cardiomyocytes stimulated for 24 hours with FGF9, BMP6, or
10% FCS (75 to 111 cells per condition in C; 4 to 5 experiments in E; **P0.01, ***P0.001 vs control). D, Images of adult cardiomyo-
cytes stimulated for 24 hours with 300 ng/mL FGF9, 10 ng/mL BMP6, or 10% FCS. F, Immunoblot analysis of BMP6, phospho-
SMAD1/5, and phospho-SMAD3 expression in the LVs of WT, tTA single transgenic, and tTA/FGF9 DTG mice 8 weeks after doxycy-
cline withdrawal (similar results were obtained in 2 additional mice per genotype).
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were not significantly different between WT, tTA, and DTG
mice (Figure 6B and Table 2). DTG animals, however,
developed more LV hypertrophy with greater LV mass and
ratio of LV mass to body mass compared with WT and tTA
mice (Figure 6B and Table 2). Body weight was not signif-
icantly different between the genotypes (not shown). En-
hanced LV hypertrophy in DTG mice was not related to
differences in tail-cuff blood pressure or heart rate after MI
(Figure I in the online-only Data Supplement, LAD ligation).
Postinfarct LV hypertrophy in DTG mice was character-
ized by a greater mean cardiomyocyte cross-sectional area, a
higher density of Ki67 isolectin B4 endothelial cells, a
greater capillary density, and an increased density of small
(20 to 50 m in diameter) SMA conductance vessels
(Table 2). DTG mice developed less interstitial fibrosis in the
noninfarcted LV myocardium compared with WT and tTA
mice (Figure 6C and 6D). Induction of atrial natriuretic
peptide and downregulation of MHC and SERCA2a mRNA
expression in the noninfarcted LV myocardium were attenu-
ated in DTG mice (Table II in the online-only Data Supple-
ment, LAD ligation).
Improved Systolic Function and Reduced Heart
Failure Mortality After MI in
FGF9-Expressing Mice
As shown by invasive pressure-volume measurements, all 3
genotypes developed LV dilatation (increased LV end-dia-
stolic volume, trend only in DTG mice) and systolic and
diastolic dysfunction 6 weeks after MI (Table 1, LAD
ligation). Systolic function, however, was more preserved in
DTG compared with WT and tTA mice, as reflected by a
smaller end-systolic volume and greater ejection fraction,
cardiac output, stroke work, and dP/dtmax (Table 1, LAD
ligation). Indexes of diastolic dysfunction (dP/dtmin,  w)
were not significantly different between DTG and control
mice after MI (Table 1, LAD ligation). Typical pressure-
volume loops are shown in Figure II in the online-only Data
Supplement. Better systolic function in DTG mice after MI
was confirmed by 2-dimensional echocardiography (Table III
in the online-only Data Supplement, LAD ligation).
Six weeks after MI, 14 of 39 WT mice (36%), 14 of 41 tTA
mice (34%), and 5 of 35 DTG mice (14%) had died with signs
of heart failure (P0.032; Figure 6E). Heart failure deaths
occurred between days 1 and 19 after LAD ligation. Rupture
deaths were observed less frequently in our FVB/N mice and
were not significantly affected by transgenic FGF9 (WT, 6 of
39, 15%; tTA, 5 of 41, 12%; DTG, 4 of 35, 11%; P0.78,
Figure 6E). To explore how transgenic FGF9 reduces early
heart failure mortality, echocardiography and LV histology
were also performed 1 week after MI. Already at this early
time point, significant increases in LV capillary density,
cardiomyocyte cross-sectional area, wall thickness, and frac-
Figure 6. FGF9 reduces interstitial fibrosis
and reduces heart failure mortality after MI.
A, Immunoblot analysis of endogenous
FGF9 expression in the noninfarcted LV
myocardium of WT mice at various time
points after LAD ligation (similar results were
obtained in 2 additional mice per time point).
B through E, Mice underwent LAD ligation 2
weeks after doxycycline withdrawal; end
points were assessed 6 weeks later. B,
Transverse sections of infarcted WT, tTA
single transgenic, and tTA/FGF9 DTG hearts
stained with Masson trichrome. C, Tissue
sections from WT, tTA, and DTG hearts
stained with Picrosirius Red and viewed
under nonpolarized (top row) or polarized
light (bottom row); images are from the non-
infarcted part of the LV (scale bar, 200 m).
D, Quantification of interstitial collagen vol-
ume fraction in the noninfarcted LV myocar-
dium (4 to 6 animals per group). E, Thirty-
nine WT, 41 tTA, and 35 DTG mice were
followed up for 6 weeks after LAD ligation.
Table 2. LV Histology 6 Weeks After LAD Ligation
WT tTA DTG
Scar length/endocardial
circumference, %
361 361 364
Scar thickness, mm 0.340.02 0.350.02 0.390.02
LV mass, mg 1193 1233 16810†
LV mass/body mass, mg/g 4.20.2 4.40.2 5.50.4*§
Cardiomyocyte CSA, m 75440 74634 89236†
Ki67 isolectin B4 cell
density (per field)
2.30.3 2.40.3 3.60.4*§
Capillary density (per CM) 1.30.1 1.30.1 1.70.1‡¶
SMA vessel density
(per 100 CMs) (20-50
m in diameter)
4.20.4 3.80.4 5.40.4*§
SMA vessel density
(per 100 CMs) (50
m in diameter)
0.260.06 0.270.10 0.370.03
CSA indicates cross-sectional area; CM, cardiomyocyte. WT, tTA single
transgenic, and tTA/FGF9 DTG mice were treated with doxycycline from mating
until 8 weeks after birth. Doxycycline was then withdrawn. Mice underwent
LAD ligation 2 weeks later and were followed up for an additional 6 weeks.
*P0.05, †P0.01, ‡P0.001 versus WT; §P0.05, P0.01, ¶P0.001
versus tTA; 5 to 9 animals per group.
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tional area change were observed in DTG mice, strongly
suggesting that LV hypertrophy with enhanced systolic func-
tion contributed to the reduction in heart failure mortality
(Table V in the online-only Data Supplement).
FGF9 Gene Transfer Improves Systolic Function
and Reduces Heart Failure Mortality After MI
To further explore the therapeutic potential of FGF9 after MI,
WT mice were treated with a single injection of Ad.FGF9 or
Ad.lacZ into the LV cavity immediately after LAD ligation
(1108 plaque-forming units [pfu] per mouse). Seven days
after adenoviral FGF9 gene transfer, FGF9 protein levels
were increased in the noninfarcted LV and liver (Figure 7A).
Increased FGF9 levels were detected in the noninfarcted LV
as early as 3 days after gene transfer (Figure 7B). As shown
by immunostaining 7 days after FGF9 gene transfer, FGF9
was expressed mostly in cardiomyocytes, with30% to 35%
of myocytes showing strong FGF9 expression (3 animals); an
example is shown in Figure 7C.
Six weeks after LAD ligation, Ad.FGF9-treated mice
displayed greater LV mass and ratio of LV mass to body mass
(Figure 7D) and better systolic function with a smaller LV
end-systolic area and greater LV fractional area change
(Figure 7E) compared with Ad.lacZ-treated mice. Infarct
sizes were not significantly different between the 2 groups
(Ad.lacZ, 383%, n6; Ad.FGF9, 374%, n8).
Six weeks after MI, 10 of 30 Ad.lacZ-treated mice (33%)
and 3 of 30 Ad.FGF9-treated mice (10%) had died with signs
of heart failure (P0.032; Figure 7F). Heart failure deaths
occurred between days 1 and 18 after LAD ligation. Rupture
deaths were observed less frequently and were not signifi-
cantly affected by FGF9 (Ad.lacZ, 2 of 30, 7%; Ad.FGF9, 3
of 30, 10%; P0.70; Figure 7F). Already 1 week after MI,
significant increases in LV capillary density, cardiomyocyte
cross-sectional area, wall thickness, and fractional area
change were observed in Ad.FGF9-treated animals, sug-
gesting again that FGF9-induced LV hypertrophy with
enhanced systolic function contributed to the reduction in
early heart failure mortality (Table VI in the online-only
Data Supplement).
Discussion
In contrast to previous investigations in transgenic mice
examining the function of FGF family members in the
myocardium,24–27 the inducible strategy used here bypassed
any developmental effects that might have occurred in em-
bryos or neonates and enabled us to explore the effects of
FGF9 specifically in the adult heart. In unstressed mice,
FGF9 stimulated concentric LV hypertrophy with microves-
sel expansion without increases in interstitial fibrosis and
with no changes in the expression levels of cardiac genes that
are typically observed during pathological hypertrophy and
heart failure. Systolic and diastolic function was preserved
in FGF9-expressing mice. FGF9-induced cardiac hypertro-
phy therefore displayed structural, molecular, and func-
tional characteristics of the adaptive hypertrophic response
that is observed after physiological increases in cardiac
workload.28 –34
In the setting of MI, transgenic FGF9 similarly promoted
microvessel expansion and enhanced cardiomyocyte hyper-
trophy in the noninfarcted LV myocardium. Infarct sizes and
scar thickness were not affected by myocardial expression of
FGF9. Enhanced interstitial fibrosis, increased expression
levels of atrial natriuretic peptide, a shift in MHC isoform
expression from  to , and decreased expression levels of
SERCA2a are hallmarks of pathological hypertrophy, which
develops in disease states with increased cardiac workload
(eg, MI, valvular heart disease, hypertension) and may
Figure 7. Adenoviral FGF9 gene transfer
improves systolic function and reduces
heart failure mortality after MI. WT mice
underwent LAD ligation followed imme-
diately by a single injection of Ad.lacZ or
Ad.FGF9 into the LV cavity (1108 pfu
each). A, Immunoblot analysis of FGF9
expression in the noninfarcted LV myo-
cardium, liver, and lung 7 days after
gene transfer. B, Time course of FGF9
protein expression in the noninfarcted LV
after FGF9 gene transfer. C, LV tissue
sections stained with WGA and an anti-
FGF9 antibody 7 days after Ad.lacZ or
Ad.FGF9 treatment (images are from the
noninfarcted LV). D, LV mass and ratio
of LV mass to body mass 6 weeks after
LAD ligation in 12 Ad.lacZ- and 14
Ad.FGF9-treated mice. E, LV end-dia-
stolic area (LVEDA), LV end-systolic area
(LVESA), and LV fractional area change
6 weeks after LAD ligation in 10 Ad.lacZ-
and 10 Ad.FGF9-treated mice (*P0.05,
**P0.01 vs Ad.lacZ). F, Thirty Ad.lacZ-
and 30 Ad.FGF9-treated mice were fol-
lowed up for 6 weeks after LAD ligation.
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ultimately lead to the development of heart failure.33,34 FGF9
antagonized these structural and molecular features of patho-
logical hypertrophy. Notably, FGF9 enhanced systolic func-
tion and reduced heart failure mortality after MI, thus clearly
establishing that expression of FGF9 in the adult mouse
myocardium is beneficial during recovery from an acute MI.
Although interstitial LV fibrosis was attenuated and LV
expression of SERCA2a was slightly augmented in FGF9-
transgenic mice after MI, these parameters were still mark-
edly abnormal compared with sham-operated mice, and
diastolic function was not significantly enhanced by trans-
genic FGF9 (trend only for improvement in dP/dtmin).
Previous studies in animal models of pathological hyper-
trophy have shown that exercise training can promote extra
LV hypertrophy with favorable changes in gene expression
signatures and, as investigated in some reports, with im-
proved systolic function.35–37 Therefore, it has been proposed
that stimulation of physiological hypertrophy, either by mod-
erate exercise or by activation of signaling pathways promot-
ing physiological hypertrophy, may be applied therapeuti-
cally in disease states, leading to pathological hypertrophy
and heart failure.29,38 Our study supports this emerging
concept and provides the first evidence that a genetic inter-
vention promoting a physiological-like increase in cardiac
mass can lead to a marked reduction in heart failure mortality
after MI. Consistent with previous reports,20,21 fatal infarct
ruptures were observed less frequently in our FVB/N mice
and were not significantly influenced by myocardial expres-
sion of FGF9 in our study.
On a histological level, microvessel expansion and cardio-
myocyte hypertrophy represented the main phenotypes of
FGF9 transgenic mice, and our data indicate that they may be
interrelated. Coordinated growth of the coronary microvas-
culature is important to ensure adequate tissue perfusion and
to maintain contractile function as the myocyte compartment
expands during cardiac development3,4,39 or exercise-induced
physiological hypertrophy.30–32 Conversely, vascular rarefac-
tion contributes to the decline in contractile function during
chronic pressure overload–induced pathological hypertro-
phy.40,41 An increase in Ki67 endothelial cells was the first
phenotype observed after FGF9 induction in the myocardium,
consistent with an initial stimulatory effect of cardiomyocyte-
derived transgenic FGF9 on endothelial cell proliferation. In
accord with this hypothesis, FGF9 stimulated angiogenesis in
several bona fide angiogenesis assays in vitro (shown for both
HCAECs and mouse cardiac endothelial cells) but did not
promote considerable cardiomyocyte hypertrophy, as shown
in neonatal and adult rat cardiomyocytes.
In the hypertrophied heart, proangiogenic cytokines are
released from cardiomyocytes and signal to adjacent capil-
laries to stimulate myocardial angiogenesis.40,41 Conversely,
enhanced myocardial angiogenesis per se can induce cardio-
myocyte hypertrophy in the absence of external stimuli, thus
suggesting the existence of reciprocal, endothelial cell–
derived prohypertrophic signals.42,43 Conditioned superna-
tants from FGF9-stimulated endothelial cells (HCAECs or
mouse cardiac endothelial cells) stimulated cardiomyocyte
hypertrophy, which was mediated in part by paracrine release
of the transforming growth factor- cytokine family member
BMP6. We found BMP6 to signal via BMP type I receptors
ALK2/3/6, to activate SMAD 1/5, and to induce hypertrophy
in neonatal and adult cardiomyocytes. BMP6 expression and
SMAD1/5 phosphorylation were increased in the myocardium
of FGF9 transgenic mice, confirming that FGF9 stimulates
BMP6 signaling also in vivo. Of the many potential second-
ary paracrine effects induced by transgenic FGF9 in the
myocardium, BMP6 therefore represents one potential mech-
anism whereby FGF9 promotes cardiomyocyte hypertrophy.
We acknowledge the general limitations of using cell culture
systems to provide mechanistic insight into in vivo
phenotypes.
We have previously shown that intracoronary infusion of
autologous BMCs enhances the recovery of systolic function
in postinfarct patients,13,44 and we have identified FGF9 as a
factor that is secreted from these cells.14 Given the results of
the present study, FGF9-mediated paracrine effects in the
border zone of the infarct may contribute to the improve-
ments in microvascular perfusion and regional contractility
that have been observed after intracoronary BMC transfer in
some clinical trials.13,16,45,46 Because FGF9 is 1 of 100
factors secreted from BMCs,14 we do not infer that FGF9
“explains” the effects of cell therapy. Moreover, it has to be
considered that our conditional transgenic and adenoviral
approaches target the remote myocardium and border zone,
whereas intracoronary cell transfer targets the border zone
and infarcted area. Different therapeutic effects may therefore
be observed in both situations (eg, hypertrophy of the remote
myocardium has not been reported after BMC transfer). In
any case, our data support the idea that secretome analyses of
BMCs can lead to the identification of secreted factors with
therapeutic activity after MI.15,16
Conclusions
Conditional expression of FGF9 in the adult mouse myocar-
dium enhances vascularization and hypertrophy, which, when
superimposed on postinfarct remodeling, promotes functional
benefits and reduces heart failure mortality. The beneficial
effects of transgenic FGF9 can be reproduced by adenoviral
FGF9 gene transfer, which should stimulate further research into
the therapeutic potential of FGF9 after MI.
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CLINICAL PERSPECTIVE
Paracrine mechanisms are thought to contribute to the beneficial effects of bone marrow cells on perfusion and function
of the infarcted heart that have been demonstrated in experimental studies and some clinical trials. We have previously
identified fibroblast growth factor 9 (FGF9) as 1 of 100 paracrine factors that are secreted from bone marrow cells after
myocardial infarction. In the embryonic heart, FGF9 is expressed by the epicardium and endocardium and provides an
epithelial-to-mesenchymal signal to stimulate coronary artery formation and cardiomyoblast expansion in the developing
myocardium. FGF9, however, is expressed only at very low levels in the adult heart. Using a tetracycline-responsive binary
transgene system based on the -myosin heavy chain promoter, we show here that conditional expression of FGF9 in the
adult mouse myocardium supports functional adaptation and survival after myocardial infarction. Transgenic FGF9
stimulated left ventricular hypertrophy with microvessel expansion, reduced interstitial fibrosis, attenuated fetal gene
expression, preserved diastolic but improved systolic function, and markedly reduced heart failure mortality. A single
injection of an adenoviral vector encoding FGF9 promoted similar improvements in left ventricular systolic function and
survival after myocardial infarction. Mechanistically, FGF9 acted primarily on endothelial cells to promote angiogenesis
and paracrine release of prohypertrophic factors, including bone morphogenetic protein 6. These observations support the
idea that secretome analyses in bone marrow cells can lead to the identification of secreted factors with therapeutic activity
after myocardial infarction. Specifically, the data suggest a previously unrecognized therapeutic potential for FGF9 after
myocardial infarction.
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SUPPLEMENTAL MATERIAL 
 
EXPANDED METHODS 
Materials 
Recombinant mouse and human fibroblast growth factor (FGF) 9, mouse bone morphogenetic 
protein (BMP) 6, a neutralizing anti-BMP6 antibody and a corresponding isotype control antibody 
were purchased from R&D Systems (Minneapolis, MN). Mouse and rat cells were stimulated with 
mouse FGF9 and BMP6, human cells with human FGF9. Endothelin 1 (ET1), dorsomorphin, an 
inhibitor of activin receptor-like kinase (ALK) 2, ALK3, and ALK6,1 and SB-431542, an inhibitor 
of ALK4, ALK5, and ALK7,2 were purchased from Sigma-Aldrich (St. Louis, MO). 
 
Inducible cardiac-specific FGF9-transgenic mice and animal procedures 
A tetracycline-responsive transgene system3 was used to allow temporally-regulated expression of 
FGF9 in adult cardiac myocytes. Mouse FGF9 cDNA was cloned into the SalI–HindIII site of the 
chimeric tetracycline-responsive α myosin heavy chain (MHC) promoter (responder mice). The 
construct was linearized and injected into FVB/N pronuclei. Founder lines were crossed with 
transgenic mice expressing the tetracycline transactivator (tTA) under the control of the 
constitutive αMHC promoter (FVB/N background). Doxycycline (Dox) was provided in the 
drinking water (625 mg/L) from mating up to 8 weeks after birth to inhibit transgenic FGF9 
expression; Dox was withdrawn thereafter, resulting in expression of FGF9. Transgenes were 
detected in genomic DNA by PCR using the primers 
5’-GTCGTAATAATGGCGGCATACTATC-3’ and 
5’-AGCGCATTAGAGCTGCTTAATGAGGTC-3’ for the tTA driver transgene, and 
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5’-GCAGGACTGGATTTCATTTAGAG-3’ and 5’-CCTGAGATTAGGAGTTGGAGAC-3’ for 
the FGF9 responder transgene. 
Myocardial infarction (MI) was induced in male mice by permanent left anterior descending 
coronary artery (LAD) ligation.4 Animals were anesthetized with 3% isoflurane and ventilated 
with 1 to 2% isoflurane (Baxter, Deerfield, IL). Control male mice underwent a sham operation 
where the ligature around the LAD was not tied. No differences in perioperative mortality rates 
(first 24 h) were observed between wild type, tTA single transgenic, and FGF9/tTA double 
transgenic mice. For an assessment of postinfarct survival, mice were followed and inspected daily 
from 24 h up to 6 weeks after surgery. Autopsies were performed on all dead animals, rupture was 
diagnosed by the presence of a blood clot around the heart and in the chest cavity, whereas heart 
failure was diagnosed by chest fluid accumulation.5,6 Six weeks after a sham operation, no deaths 
were observed in any of the genotypes. All animal procedures were approved by our local state 
authorities. 
  
Adenoviral FGF9 gene transfer  
Mouse FGF9 cDNA was cloned into a replication-deficient adenovirus using the AdEasy XL 
Vector System (Stratagene, La Jolla, CA). A replication-deficient adenovirus encoding 
β-galactosidase was used as control. Viruses were purified with the Adeno-X Virus Purification 
Kit (BD Biosciences, Franklin Lakes, NJ). Viruses were injected into the left ventricular (LV) 
cavity immediately after LAD ligation. 
 
In vivo pressure-volume measurements 
Left ventricular pressure-volume (P-V) loops were recorded with a 1.4 F micromanometer 
conductance catheter (SPR-839, Millar Instruments, Houston, TX) inserted via the right carotid 
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artery during isoflurane (2%) anesthesia. Steady-state P-V loops were sampled at a rate of 1 kHz 
and analyzed by a sample-blinded investigator (T.K.). 
 
Echocardiography 
Transthoracic echocardiography was performed with a linear 30 MHz transducer (VisualSonics, 
Toronto, Canada) in mice that were sedated with 1 to 1.5% isoflurane and placed on a heating pad 
to maintain body temperature. LV end-diastolic area (LVEDA) and end-systolic area (LVESA) 
were recorded from the long-axis parasternal view. Fractional area change was calculated as 
[(LVEDA–LVESA)/LVEDA] × 100. 
 
Histology 
Left ventricles were fixed in phosphate-buffered 4% formaldehyde and embedded in paraffin. 
Sections (5 µm in thickness) were cut from basal, midventricular, and apical LV slices and stained 
with Masson’s trichrome which shows fibrosis in blue. To determine infarct size, scar length and 
total LV circumference were traced at the endocardial surface. Infarct sizes were calculated as the 
average ratio of scar length to total LV circumference in basal, midventricular, and apical sections. 
Scar thickness was measured at the center of the infarct in the same sections and averaged.  
For fluorescent (immuno)staining, midventricular slices of the left ventricle were embedded 
in OCT compound and frozen at -80°C. Cryosections (5 µm in thickness) were stained with 
TRITC-conjugated wheat germ agglutinin (WGA, Sigma-Aldrich) to outline cardiomyocytes. The 
circumferences of 40 to 50 myocytes were traced and digitized to calculate mean cardiomyocyte 
cross-sectional area. Only cells from fields with circular myocyte shapes (indicative of a transverse 
section) were analyzed. Ki67 was detected with a rabbit polyclonal antibody and a Cy5-labeled 
secondary antibody from Abcam (Cambridge, MA). Fluorescein-labeled GSL I-isolectin B4 
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(Vector Laboratories, Burlingame, CA) was used to visualize capillaries. Conductance vessels 
were identified by their diameter (>20 µm) after immunostaining for smooth muscle α-actin 
(SMA) using a mouse monoclonal antibody from Sigma-Aldrich and a FITC-labeled secondary 
antibody from Abcam. Troponin T was visualized with a mouse monoclonal antibody from Abcam 
and an Alexa Fluor 594-labeled secondary antibody from Invitrogen (Carlsbad, CA). Interstitial 
collagen content was determined by picrosirius red polarization microscopy. Interstitial collagen 
volume fraction was calculated as the sum of all connective tissue areas divided by the sum of all 
connective tissue and muscle areas in the respective field. Perivascular areas were not included in 
the analysis. Images were acquired with an Axiovert microscope (Carl Zeiss, Jena, Germany). 
 
Quantitative PCR (qPCR) 
Total RNA was extracted from LV myocardium by TRIzol (Invitrogen) and purified with RNeasy 
kits (Qiagen, Hilden, Germany). After reverse transcription (Superscript II, Invitrogen), qPCR was 
performed using the Brilliant SYBR Green Mastermix-Kit and the MX4000 multiplex QPCR 
System from Stratagene (PCR primers are shown in Supplemental Table 1). 
 
Cell culture 
Human coronary artery endothelial cells (HCAECs) were purchased from Provitro (Berlin, 
Germany) and grown in MCDB131 medium (Invitrogen) supplemented with 10% FCS. Cells from 
passage 3 to 7 were used. Mouse heart endothelial cells were isolated from 10-day old C57/BL6 
mice as previously described.7 In brief, ventricles were digested in collagenase I solution 
(265 U per heart) followed by magnetic cell sorting using Dynabeads (Invitrogen) coated with a rat 
anti-mouse CD31 monoclonal antibody (BD Biosciences). Prior to their use in functional assays, 
endothelial cells were cultured overnight in MCDB131 (HCAECs) or D-MEM/high glucose 
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medium (mouse endothelial cells) containing 0.5% FCS. Endothelial cell proliferation was 
measured by bromodeoxyuridine incorporation in 96-well plates (5 × 103 cells per well). Network 
formation was assayed in 24-well plates (3 × 104 cells per well) coated with growth factor-reduced 
Matrigel (BD Biosciences).8 
Ventricular cardiomyocytes were isolated from 1 to 3-day-old Sprague-Dawley rats by 
Percoll density gradient centrifugation.8 Cell size was determined by planimetry, protein content 
by the Bradford assay. Adult ventricular cardiomyocytes were isolated from 4-month-old Wistar 
rats.9 Cross-sectional area of adult cardiomyocytes was calculated as (cell width/2)² × pi. 
Net protein synthesis was measured by [14C] phenylalanine incorporation.  
 
Immunoblotting 
Antibodies against mouse FGF9 (Genway Biotech, San Diego, CA), BMP6 (Santa Cruz 
Biotechnology, Santa Cruz, CA), phospho-SMAD1/5, phospho-SMAD3, and β-actin (Cell 
Signaling Technology, Danvers, MA) were used for immunoblotting. 
 
Antibody array 
HCAECs (1 × 106 cells) were cultured in 2 mL MCDB131 without FCS for 24 h in the presence or 
absence of FGF9 (10 ng/mL). Human Cytokine ProteinChip Array C Series 2000 membranes 
(Ray Biotech, Norcross, GA) targeting 174 secreted factors were incubated with 1 mL of 
conditioned HCAEC supernatant for 2 h, washed, and sequentially incubated with biotinylated 
antibodies, horseradish peroxidase-conjugated strepavidin, and detection solution according to the 
manufacturer’s instructions. 
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Supplemental Table 1. PCR primers 
 Forward Reverse 
ANP 
 
5’-GTGGCTTGTGGGAAAATA
GTTGA-3’ 
5’-CTGGCTTGATGATCTGCCT
TTAC-3’ 
αMHC 5’-CCAATGAGTACCGCGTGA
A-3’ 
5’-ATGTGCCGGACCTTGGAA-
3’ 
βMHC 5’-CTTGTTGACCTGGGACTCG
G-3’ 
5’-ACCTGTCCAAGTTCCGCAA
G-3’ 
SERCA2a 5’-TGTTCATTCTGGACAGAGT
GGAAGG-3’ 
5’-TTAATAAAGTTGGCAGAGT
CCTCAAGG-3’ 
Phospholamban  
 
5’-TCAGAGAAGCATCACGAT
GATACAGATCAG-3’ 
5’-ATGGAAAAAGTGCAATAC
CTCACTCGC-3’ 
GAPDH 5’-GCAGGATGCATTGCTGAC
AATC-3’ 
5’-CTGAGTATGTCGTGGAGTC
TACTG-3’ 
ANP, atrial natriuretic peptide; MHC, myosin heavy chain; SERCA2a, sarco(endo)plasmic reticulum 
Ca2+ ATPase-2a; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
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Supplemental Table 2. Gene expression levels 6 weeks after sham operation or LAD ligation 
 WT tTA DTG 
Sham 
ANP 100 ± 15 86 ± 16 90 ± 10 
αMHC  100 ± 10 116 ± 8 97 ± 5 
βMHC 100 ± 4 97 ± 11 90 ± 19 
SERCA2a 100 ± 6 78 ± 10 86 ± 7 
Phospholamban 100 ± 9 94 ± 2 104 ± 5 
LAD ligation 
ANP 895 ± 105** 937 ± 94*** 505 ± 197**,†,‡ 
αMHC  29 ± 15*** 39 ± 16*** 83 ± 21††,‡‡ 
βMHC 113 ± 7 116 ± 2 110 ± 5 
SERCA2a 16 ± 2** 20 ± 4*** 34 ± 4**,†,‡ 
Phospholamban 67 ± 9 67 ± 9 69 ± 11 
WT, tTA single transgenic, and tTA/FGF9 double transgenic (DTG) mice were treated with Dox from 
mating until 8 weeks after birth. Dox was then withdrawn. Mice underwent a sham operation or LAD 
ligation 2 weeks after Dox withdrawal. LV gene expression levels were determined by qPCR 6 weeks 
later (non-infarcted LV myocardium in infarcted mice). Data were normalized to glyceraldehyde-3-
phosphate dehydrogenase expression and expressed as (%) of sham-operated WT mice. ANP, atrial 
natriuretic peptide; MHC, myosin heavy chain; SERCA2a, sarco(endo)plasmic reticulum 
Ca2+ ATPase-2a. **P<0.01, ***P<0.001 vs. same genotype sham; †P<0.05, ††P<0.01 vs. WT LAD 
ligation; ‡P<0.05, ‡‡P<0.01 vs. tTA LAD ligation; 5-6 animals per group. 
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Supplemental Table 3. Echocardiography 6 weeks after sham operation or LAD ligation 
 WT tTA DTG 
Sham 
Heart rate (min-1) 461 ± 12 453 ± 11 443 ± 25 
LV posterior wall thickness (mm) 1.23 ± 0.05 1.22 ± 0.05 1.34 ± 0.03†,‡ 
LV end-diastolic area (mm²) 26.4 ± 0.5 26.8 ± 0.6 27.4 ± 0.5 
LV end-systolic area (mm²) 15.6 ± 0.5 16.5 ± 0.6 16.3 ± 0.4 
LV fractional area change (%) 41.3 ± 1.1 38.7 ± 1.3 41.2 ± 1.1 
LAD ligation 
Heart rate (min-1) 444 ± 18 449 ± 13 418 ± 13 
LV posterior wall thickness (mm) 1.44 ± 0.08** 1.38 ± 0.11* 1.69 ± 0.07***,†,‡‡ 
LV end-diastolic area (mm²) 34.0 ± 1.3** 33.3 ± 2.0** 31.8 ± 1.0** 
LV end-systolic area (mm²) 28.0 ± 1.6*** 27.8 ± 2.1*** 22.2 ± 1.5***,†,‡ 
LV fractional area change (%) 18.3 ± 2.5*** 17.9 ± 2.4*** 29.1 ± 2.6***,†,‡ 
WT, tTA single transgenic, and tTA/FGF9 double transgenic (DTG) mice were treated with Dox from 
mating until 8 weeks after birth. Dox was then withdrawn. Mice underwent a sham operation or LAD 
ligation 2 weeks after Dox withdrawal. Echocardiography was performed 6 weeks later. LV, left 
ventricular. *P<0.05, **P<0.01, ***P<0.001 vs. same genotype sham; †P<0.05 vs. WT sham or WT 
LAD ligation; ‡P<0.05, ‡‡P<0.01 vs. tTA sham or tTA LAD ligation; 8-13 animals per group. 
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Supplemental Table 4. Secreted factors induced by FGF9 in HCAECs 
Array #1 Array #2  Average 
induction Control FGF9 x-fold Control FGF9 x-fold 
BMP6 4.7 16757 41250 2.5 7055 47740 6.8 
IGFBP4 3.7 30518 61296 2.0 10660 57043 5.4 
CXCL13 3.1 6849 22901 3.3 20105 55765 2.8 
BMP4 2.8 20032 46847 2.3 16979 55647 3.3 
IL10 2.3 5646 11051 2.0 14607 38312 2.6 
FGF6 2.3 13047 30197 2.3 16452 36964 2.2 
IL6 2.2 30877 62891 2.0 192737 434177 2.3 
CCL2 2.2 59196 133467 2.3 79456 160433 2.0 
PDGFA 2.1 20369 42035 2.1 33555 70668 2.1 
Human coronary artery endothelial cells (HCAECs) were kept under control conditions or stimulated with 
10 ng/mL FGF9 for 24 h. Antibody arrays detecting 174 secreted factors were incubated with conditioned 
HCAEC supernatants. Data from two independent experiments are shown. Nine secreted factors were 
induced ≥2-fold by FGF9 in both experiments, and are listed here according to their average (mean) 
induction by FGF9 vs. control. BMP, bone morphogenetic protein; IGFBP4, insulin-like growth factor 
binding protein 4; CXCL13, chemokine (C-X-C motif) ligand 13; IL, interleukin; FGF6, fibroblast growth 
factor 6; CCL2, chemokine (C-C motif) ligand 2; PDGFA, platelet-derived growth factor α polypeptide. 
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Supplemental Table 5. Echocardiography and histology 1 week after LAD ligation 
 WT tTA DTG 
Heart rate (min-1) 498 ± 17 441 ± 13 473 ± 13 
LV posterior wall thickness (mm) 1.18 ± 0.13 1.29 ± 0.06 1.55 ± 0.06*,† 
LV end-diastolic area (mm²) 27.7 ± 1.4 24.1 ± 0.6 23.5 ± 0.9 
LV end-systolic area (mm²) 21.7 ± 1.3 19.4 ± 1.1 14.6 ± 0.8**,† 
LV fractional area change (%) 20.7 ± 1.4 20.3 ± 2.7 36.6 ± 2.1***,† 
Cardiomyocyte CSA (µm²) 582 ± 29 494 ± 27 806 ± 9*,† 
Capillary density (per CM) 1.1 ± 0.0 1.1 ± 0.0 1.3 ± 0.1*,† 
WT, tTA single transgenic, and tTA/FGF9 double transgenic (DTG) mice were treated with Dox from 
mating until 8 weeks after birth. Dox was then withdrawn. Mice underwent LAD ligation 2 weeks 
after Dox withdrawal. Echocardiography and histological analyses (non-infarcted left ventricle) were 
performed 1 week later. LV, left ventricular; CSA, cross sectional area; CM, cardiomyocyte. *P<0.05, 
**P<0.01, ***P<0.001 vs. WT; †P<0.05 vs. tTA; 5-7 animals per group.
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Supplemental Table 6. Echocardiography and histology 1 week after LAD ligation 
 Ad.lacZ Ad.FGF9 
Heart rate (min-1) 446 ± 12 445 ± 5 
LV posterior wall thickness (mm) 1.29 ± 0.04 1.52 ± 0.06* 
LVEDA (mm²) 30.4 ± 1.4 26.7 ± 1.2 
LVESA (mm²) 27.8 ± 1.3 21.3 ± 1.5* 
LV fractional area change (%) 10.3 ± 1.1 21.0 ± 2.8* 
Cardiomyocyte CSA (µm²) 608 ± 21 823 ± 28*** 
Capillary density (per CM) 1.2 ± 0.0 1.5 ± 0.1* 
Wild-type mice underwent LAD ligation immediately followed by a single injection of Ad.lacZ or 
Ad.FGF9 into the left ventricular (LV) cavity (1 × 108 p.f.u., each). Echocardiography and histological 
analyses (non-infarcted left ventricle) were performed 1 week later. CSA, cross sectional area; CM, 
cardiomyocyte. *P<0.05, ***P<0.001 vs. Ad.lacZ; 4-9 animals per group. 
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SUPPLEMENTAL FIGURE LEGENDS 
Supplemental Figure 1. Tail-cuff blood pressure 
WT, tTA single transgenic, and tTA/FGF9 double transgenic (DTG) mice were treated with Dox 
from mating until 8 weeks after birth. Dox was then withdrawn. Mice underwent a sham operation 
or LAD ligation at the age of 10 weeks, and were followed for an additional 6 weeks. Serial 
tail-cuff (A) blood pressure and (B) heart rate measurements were obtained in awake mice. The 
number of animals is shown in each bar. 
  
Supplemental Figure 2. Left ventricular pressure-volume loops 
WT, tTA single transgenic, and tTA/FGF9 double transgenic (DTG) mice were treated with Dox 
from mating until 8 weeks after birth. Dox was then withdrawn. Mice underwent a sham operation 
or LAD ligation 2 weeks after Dox withdrawal. Invasive left ventricular (LV) pressure-volume 
(P-V) measurements were performed 6 weeks later. Typical steady-state P-V loops are shown. 
  
Supplemental Figure 3. FGF9 does not increase protein content in neonatal cardiomyocytes 
Protein content of neonatal cardiomyocytes stimulated for 24 h with 100 nmol/L endothelin 1 
(ET1) or increasing concentrations of FGF9 (4 experiments; *P<0.05 vs. control). 
 
Supplemental Figure 4. BMP6 increases protein content in neonatal cardiomyocytes in an 
ALK2/3/6-dependent manner 
Protein content of neonatal cardiomyocytes stimulated for 24 h with 100 nmol/L endothelin 1 
(ET1) or increasing concentrations of BMP6. Where indicated, cells were treated with the 
ALK2/3/6 inhibitor dorsomorphin (DM, 20 µmol/L) or the ALK4/5/7 inhibitor SB-431542 
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(SB, 20 µmol/L) (4 experiments; *P<0.05 vs. control). 
 
Supplemental Figure 5. FGF9 stimulates mouse endothelial cell proliferation, network 
formation, and release of pro-hypertrophic BMP6  
(A) Proliferation and (B) network formation of mouse heart endothelial cells (MHEC) stimulated 
for 24 h with 10 ng/mL vascular endothelial growth factor (VEGF) or increasing concentrations of 
FGF9 (4 experiments; *P<0.05, **P<0.01 vs. control). (C and D) Neonatal cardiomyocytes were 
cultured for 24 h in the absence (control) or presence of endothelin 1 (ET1, 100 nmol/L). 
Additional cardiomyocytes were stimulated for 24 h with supernatant (SN, 1:2 dilution) obtained 
from MHEC kept for 24 h in serum-free medium (control), or supernatant obtained from MHEC 
stimulated for 24 h with 10 ng/mL FGF9; (C) cell size and (D) protein content were determined 
(n=9). Where indicated, a BMP6 neutralizing antibody or a control antibody (20 µg/mL, each) was 
added to the supernatants. 
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Supplemental Figure 2
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